In contrast, treatment with Rimo-NPs affected only insulin sensitivity, reflected by the reduced glucose levels, following a bolus of insulin, reduced hyperinsulinemia, and improved HOMA-IR and ISI levels (Fig. 7d-h). The gene discussed is INS; the disease is hyperinsulinism.